QTX3034 + cetuximab ± mFOLFOX6 in KRAS G12D mCRC: preliminary results

Evelyn Wong· @EvelynWongYT · X·2026-10-24 21:28· 16 小时前评分70

正文 · 原文

QTX3034 + cetuximab ± mFOLFOX6 in KRAS G12D mCRC: preliminary results
👉 ORR: 25% vs 50%
👉 DCR: 75% vs 90%
Encouraging signal for adding chemotherapy. small cohorts; durability & comparative data needed!
#ESMO26 #ESMOAmbassadors @OncoAlert

41 浏览 · 1 赞 · 1 转发 · 0 回复

会议摘要

788RO按 Rapid oral: Gastrointestinal tumours, lower digestive 对上

Encorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial

https://esmocongress.esmo.org

NCT06578559NCT06578559按 - **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC 对上

- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

https://esmocongress.esmo.org

NCT06640166NCT06640166按 - **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. 对上

- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

https://esmocongress.esmo.org

来源：Evelyn Wong · x.com